👋 Hey, let’s get into it. The GLP-1 pill race just turned into a real two-player fight.

The FDA just approved Eli Lilly’s oral weight loss pill, Foundayo, putting it head-to-head with Novo Nordisk’s oral Wegovy. On efficacy, Novo still appears to have the edge, with stronger weight loss numbers based on current data. But Lilly is closing the gap enough that the decision may come down to tradeoffs rather than clear superiority.

Convenience is where things get interesting. Both are pills, but real-world use, tolerability, and how easy they are to stay on could start to separate them once millions of patients enter the market. Then there’s pricing. Early signals suggest they’re competing in a similar range, which means neither company is giving up margin to win share.

Put it all together, and this is no longer about who has the best drug, it’s about who builds the better product experience at scale.

FYI: This is a Lilly-heavy edition of BioNucleus Briefing…sorry to all the Novo fans out there.

😴 Lilly Drops $6.3B on Sleep Science
Eli Lilly is going deeper into neuroscience with a $6.3 billion acquisition of Centessa Pharmaceuticals, betting big on orexin biology to treat sleep disorders. The prize is cleminorexton, a mid-stage asset showing strong improvements in wakefulness and narcolepsy symptoms. Lilly is paying a premium plus milestone-heavy upside, signaling real conviction in the data. More broadly, this expands Lilly’s footprint beyond metabolic dominance into CNS, where effective treatments remain scarce and commercially massive.

💰 Biogen Buys Growth With $5.6B Apellis Deal
Biogen is acquiring Apellis Pharmaceuticals for $5.6 billion, adding two commercial-stage drugs to its portfolio. The deal brings Syfovre and Empaveli, which generated nearly $700 million last year, giving Biogen immediate revenue and expansion into immunology and nephrology. Investors sent Apellis shares soaring while Biogen dipped, a classic “buyer pays” reaction. Still, Biogen is clearly prioritizing near-term growth over pipeline patience.

❤️ Novo Expands Wegovy Into Heart Disease Prevention
Novo Nordisk just unlocked a new lane for Wegovy, with UK regulators backing its use to prevent heart attacks and strokes. The recommendation targets high-risk patients already on standard therapies, potentially expanding access to over a million people. This is a major shift: GLP-1s are no longer just weight loss drugs, they are becoming cardiovascular medicines. That positioning could significantly widen the long-term market.

🇬🇧 Lilly Pushes UK Pricing Showdown
Eli Lilly is pressuring the UK to raise drug prices and ease rebate policies in exchange for restarting investment. After pausing spending last year, the company is now negotiating directly with policymakers, arguing the current system discourages innovation. Leadership sounds optimistic about a deal by summer. The bigger signal: pharma is getting more aggressive in tying capital deployment to pricing environments.

💰 Blackstone Closes Record $6.3B Fund
Blackstone just raised the largest private life sciences fund ever, pushing its total assets in the space to $15 billion.

⚠️ FDA Flags Deaths Linked to Amgen Drug
The FDA cited 8 deaths and 76 liver injury cases tied to Tavneos, escalating a standoff after Amgen refused to pull it.

🔎 Merck Expands Antibody Hunt
Merck inked an $838 million discovery deal with Infinimmune, tapping human memory B-cell data for next-gen antibodies.

⚖️ Novo Faces Drug Deal Fallout
KBP Biosciences is trying to reclaim a heart drug from Novo after fraud allegations and a failed $1.3 billion agreement.

💊 Ambrosia Raises $100M for Oral GLP-1
The startup is pushing beyond peptides, advancing a small-molecule obesity drug into Phase 1 trials.

🏭 Novo Cuts 400 Indiana Jobs
Novo is downsizing its Indiana site as part of a broader production overhaul tied to GLP-1 scaling.

🫁 United Eyes IPF Filing
Two strong Phase 3 wins position Tyvaso as a potential new standard for a deadly lung disease.

We just entered Q2, and the FDA’s decision calendar is already stacked with high-impact calls that could ripple across multiple therapeutic areas.

The tone was set right at the end of Q1. Biogen secured FDA approval for a high-dose version of Spinraza on March 30, giving the company a much-needed win just days before the quarter flipped. The updated regimen cuts down the number of loading doses while maintaining efficacy, potentially improving patient experience and helping Biogen stay competitive in an SMA market increasingly shaped by gene therapies and oral alternatives.

Then, on April 1, Eli Lilly wasted no time making its mark on Q2 with the approval of its oral GLP-1 pill, Foundayo. The once-daily pill showed roughly 12.5% weight loss in trials and is priced in line with Novo’s competing pill, immediately raising the stakes in the obesity market.

Beyond those early decisions, the rest of the quarter is packed with high-conviction catalysts.

Replimune is back in front of the FDA with RP1, an oncolytic virus designed to selectively infect tumors while triggering a broader immune response. Its prior review raised questions around trial design and endpoints, so this decision will be closely watched as a signal of how the FDA is evaluating novel immunotherapy platforms.

Axsome Therapeutics is awaiting a decision on AXS-05 for Alzheimer’s agitation, a condition with limited treatment options and significant unmet need. A positive outcome would open up a large, underserved patient population and further validate Axsome’s CNS strategy.

Meanwhile, AstraZeneca is advancing baxdrostat, a hypertension drug targeting aldosterone pathways. It is a crowded space, but one where true differentiation, especially in resistant hypertension, could translate into a meaningful commercial opportunity.

Layered on top of all this is a shifting regulatory backdrop. Leadership changes, evolving expectations around clinical evidence, and broader policy pressure are all influencing how decisions are being made. Each approval or rejection this quarter is doing double duty: determining the fate of a drug while also offering clues about how the FDA is operating right now.

That is how much biopharma spent on M&A in Q1 across 19 deals. The pace accelerated late, with ~$20 billion deployed in just the final week. Dealmaking is back, and big pharma is not waiting around.

Here’s what biotech Redditors are talking about:

🎬 Scientists vs Hollywood Accuracy
A Reddit thread had scientists collectively losing it over Project Hail Mary showing an unbalanced centrifuge. For lab veterans, it was pure chaos. Book readers quickly jumped in to defend it, pointing out the use of futuristic self-balancing systems. The real takeaway: nothing breaks immersion faster than bad lab technique…unless it is technically correct sci-fi.

🥨 The “Snack Indicator” for Layoffs
One intern asked if losing free snacks meant layoffs were coming. The internet responded with a mix of sarcasm and realism. Most agreed it is probably just a missed order, not a corporate death signal. Still, the fact this question exists says a lot about today’s job market anxiety.

🌍 Iran Conflict Disrupts 8,000 Trial Sites
Geopolitical tensions are hitting clinical research, with thousands of trial sites impacted across the Middle East.

🚀 11 Startups Join National Accelerator
A new cohort of biotech and diagnostics startups just got selected to scale breakthrough science.

📈 Obesity Startup Eyes IPO
Kailera is testing the IPO waters with a late-stage GLP-1 competitor already backed by $1 billion.

🏭 BASF Raises API Prices 20%
Rising energy costs are pushing up drug manufacturing inputs, adding pressure across pharma supply chains.

🧠 R3 Bio Wants to Build Backup Human Bodies
R3 Bio just stepped out of stealth with one of the wildest concepts in biotech: nonsentient “organ sacks” grown for transplantation. The long-term vision goes even further, hinting at brain transplants into cloned bodies. It sounds like sci-fi (or horror), because it basically is. But the company has funding, a roadmap, and just enough plausibility to make you slightly uncomfortable about the future.

☣️ April 2, 1979 — The Soviet Anthrax Leak
A Soviet bioweapons facility accidentally released anthrax spores into the city of Sverdlovsk, killing at least 68 people. Officials blamed contaminated meat for years, but the truth eventually emerged: it was a biological weapons accident. The incident became one of the clearest signals that the Soviet Union had an active bioweapons program, despite public denials.

If you’re annoyed your company cut back on free snacks, look on the bright side…you could be in a 1979 Soviet lab working with a deadly pathogen.

Perspective helps.

We try to keep a “snack jar half full” mindset here at BioNucleus.

That’s all for today. See you Tuesday for the next issue. 👋

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead